<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03214822</url>
  </required_header>
  <id_info>
    <org_study_id>H2MF Study</org_study_id>
    <nct_id>NCT03214822</nct_id>
  </id_info>
  <brief_title>Human-derived Human Milk Fortifiers (H2MF), Gut Microbiota and Oxidative Stress in Premature Infants</brief_title>
  <official_title>The Impact of Human-derived Human Milk Fortifiers (H2MF) on Gut Microbiota Development and Oxidative Stress in Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Manitoba Developmental Origins of Chronic Diseases in Children Network (DEVOTION)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prolacta Bioscience</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial of a human-derived human milk fortifier (H2MF) vs
      standard bovine-derived human milk fortifier (HMF) evaluating fecal microbiota and fecal and
      urinary biomarkers of oxidative stress in premature infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While breast milk provides complete nutrition for full term infants, supplementation with
      human milk fortifiers (HMF) is required to achieve optimal weight gain in very low
      birthweight (VLBW) preterm neonates. Traditionally, HMF have been derived from bovine milk.
      Bovine-based infant formula has been shown to cause dysbiosis of the infant gut microbiome
      (Azad et al 2013) and increased oxidative stress in preterm neonates (Friel et al 2011).
      Microbiome dysbiosis and oxidative stress have been implicated in numerous inflammatory
      conditions, including both acute (eg. necrotizing enterocolitis, NEC) and long-term (eg.
      asthma, metabolic syndrome) sequela of preterm birth (Torrazza et al 2013, Goulet et al 2015,
      Flora et al 2007, Perrone et al 2014). Recent studies show that new human-derived HMF (H2MF)
      are superior to standard bovine HMF for nourishing VLBW preterm infants and preventing NEC
      (Sullivan et al 2010, Cristofalo et al 2013). However, the biological basis for these
      clinical benefits is unknown, which limits our ability to inform and improve feeding
      strategies for VLBW preterm infants. This will be the first study to evaluate the impact of
      H2MF on gut microbiota and oxidative stress in preterm infants.

      Specific Objectives:

        1. To evaluate the effect of H2MF vs. HMF on gut microbiota composition in premature
           infants born &lt;1250 gr between 26 and 30 weeks of gestational age.

        2. To evaluate the effect of H2MF vs. HMF on fecal and urinary biomarkers of oxidative
           stress in premature infants born &lt;1250 gr between 26 and 30 weeks of gestational age.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Using a randomized, controlled, un-blinded parallel design we will enroll 30 VLBW premature neonates (birth weight &lt; 1250 grams, gestational age 26+0 to 30+0 weeks) from the NICU at the Health Sciences Centre Children's Hospital in Winnipeg, MB, Canada. Currently, H2MF is not routinely used in this population at this centre.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking of care providers is not feasible since the procedures of preparation for HMF and H2MF are different. Outcome assessors (personnel analyzing microbiome profiles and oxidative stress biomarkers) will be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fecal microbiome composition at end of intervention</measure>
    <time_frame>33+0 weeks adjusted gestational age (end of intervention)</time_frame>
    <description>Relative abundance of operational taxonomic units (OTUs) determined by 16S rRNA Illumina sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal microbiome diversity at end of intervention</measure>
    <time_frame>33+0 weeks adjusted gestational age (end of intervention)</time_frame>
    <description>Shannon diversity index of microbiota, determined by 16S rRNA Illumina sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal microbiome community structure at end of intervention</measure>
    <time_frame>33+0 weeks adjusted gestational age (end of intervention)</time_frame>
    <description>Principal coordinate analysis using UniFrac distance matrices based on 16S rRNA Illumina sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiome at 1 week after intervention begins</measure>
    <time_frame>Study day 7 (1 week after intervention begins)</time_frame>
    <description>Fecal microbiome composition, diversity and community structure from 16S rRNA Illumina Sequencing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiome at 2 weeks after intervention ends</measure>
    <time_frame>35+0 weeks adjusted gestational age (2 weeks after intervention ends)</time_frame>
    <description>Fecal microbiome composition, diversity and community structure from 16S rRNA Illumina Sequencing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress (urinary biomarkers) at end of intervention</measure>
    <time_frame>33+0 weeks adjusted gestational age (end of intervention)</time_frame>
    <description>F2-isoprostanes, 8-hydroxy deoxyguanine, and visfatin measured in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress (fecal calprotectin) at end of intervention</measure>
    <time_frame>33+0 weeks adjusted gestational age (end of intervention)</time_frame>
    <description>Calprotectin measured in feces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress at 1 week after intervention begins</measure>
    <time_frame>Study day 7 (1 week after intervention begins)</time_frame>
    <description>Fecal and urinary biomarkers of oxidative stress (fecal calprotectin, urinary F2-isoprostanes, urinary 8-hydroxy deoxyguanine, urinary visfatin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress at 2 weeks after intervention ends</measure>
    <time_frame>35+0 weeks adjusted gestational age (2 weeks after intervention ends)</time_frame>
    <description>Fecal and urinary biomarkers of oxidative stress (fecal calprotectin, urinary F2-isoprostanes, urinary 8-hydroxy deoxyguanine, urinary visfatin).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Very Low Birth Weight Baby</condition>
  <condition>Premature Birth</condition>
  <condition>Microbial Colonization</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>HMF (standard of care)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The HMF &quot;Control Group&quot; will receive the current standard feeding protocol of human milk fortified with bovine (cow) human milk fortifier (HMF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H2MF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The H2MF &quot;Intervention Group&quot; will receive identical treatment with human-derived human milk fortifier (H2MF) replacing standard bovine HMF until the baby reaches an adjusted gestation age of 33 weeks; followed by a 5 day ween to standard HMF according to the manufacturer's recommendation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>H2MF</intervention_name>
    <description>As described in the Experimental Arm description.</description>
    <arm_group_label>H2MF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female infant with birth weight &lt;1250 grams

          -  Gestational age between 26+0 to 30+0 weeks at birth

          -  Able to adhere to feeding protocol

          -  Parenteral nutrition must be started by day of life 2

          -  Enteral feeding &gt;80 ml/kg/d should be reached by day of life 14

          -  Subject's parent(s)/legal guardian(s) has provided signed and dated informed consent
             and authorization to use protected health information, as required by national and
             local regulations.

          -  In the investigator's opinion, the subject's parent(s)/legal guardian(s) understands
             and is able to comply with protocol requirements, instructions, and protocol-stated
             restrictions, and is likely to complete the study as planned.

        Exclusion Criteria:

          -  Gestational age &gt; 30+0 weeks at birth (to guarantee a minimum of 3 weeks H2MF
             treatment, since fortification ends at 33+0 AGA)

          -  Gestational age &lt; 26+0 weeks at birth (to minimize baseline heterogeneity, since
             gestational age influences gut microbiota)

          -  Received antibiotics on the first day of specimen collection (to minimize baseline
             heterogeneity, since antibiotics influence gut microbiota) Note: all infants are
             expected to receive up to 48 hr antibiotic prophylaxis at birth according to standard
             NICU protocol; this criterion will exclude infants receiving extended courses of
             antibiotics.

          -  Received probiotics at any time (to minimize baseline heterogeneity, since probiotics
             influence gut microbiota)

          -  Unlikely to survive the study period

          -  Presence of clinically significant congenital heart disease or other major congenital
             malformation

          -  Presence prior to enrollment of intestinal perforation or stage 2 necrotizing
             enterocolitis (NEC) prior to tolerating fortified feeds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meghan Azad, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geert T'Jong</last_name>
    <role>Study Director</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Narvey, MD</last_name>
    <phone>2047872720</phone>
    <email>mnarvey@hsc.mb.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeannine Schellenberg, RN</last_name>
    <phone>2047893206</phone>
    <email>jschellenberg@chrim.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannine Schellenberg, RN</last_name>
      <phone>204.789-3206</phone>
      <email>jschellenberg@chrim.ca</email>
    </contact>
    <contact_backup>
      <last_name>Michael Narvey, MD</last_name>
      <email>mnarvey@exchange.hsc.mb.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Azad MB, Konya T, Maughan H, Guttman DS, Field CJ, Chari RS, Sears MR, Becker AB, Scott JA, Kozyrskyj AL; CHILD Study Investigators. Gut microbiota of healthy Canadian infants: profiles by mode of delivery and infant diet at 4 months. CMAJ. 2013 Mar 19;185(5):385-94. doi: 10.1503/cmaj.121189. Epub 2013 Feb 11.</citation>
    <PMID>23401405</PMID>
  </reference>
  <reference>
    <citation>Friel JK, Diehl-Jones B, Cockell KA, Chiu A, Rabanni R, Davies SS, Roberts LJ 2nd. Evidence of oxidative stress in relation to feeding type during early life in premature infants. Pediatr Res. 2011 Feb;69(2):160-4. doi: 10.1203/PDR.0b013e3182042a07.</citation>
    <PMID>21045751</PMID>
  </reference>
  <reference>
    <citation>Torrazza RM, Ukhanova M, Wang X, Sharma R, Hudak ML, Neu J, Mai V. Intestinal microbial ecology and environmental factors affecting necrotizing enterocolitis. PLoS One. 2013 Dec 30;8(12):e83304. doi: 10.1371/journal.pone.0083304. eCollection 2013.</citation>
    <PMID>24386174</PMID>
  </reference>
  <reference>
    <citation>Goulet O. Potential role of the intestinal microbiota in programming health and disease. Nutr Rev. 2015 Aug;73 Suppl 1:32-40. doi: 10.1093/nutrit/nuv039. Review.</citation>
    <PMID>26175488</PMID>
  </reference>
  <reference>
    <citation>Flora SJ. Role of free radicals and antioxidants in health and disease. Cell Mol Biol (Noisy-le-grand). 2007 Apr 15;53(1):1-2.</citation>
    <PMID>17535753</PMID>
  </reference>
  <reference>
    <citation>Perrone S, Tataranno ML, Santacroce A, Negro S, Buonocore G. The role of oxidative stress on necrotizing enterocolitis in very low birth weight infants. Curr Pediatr Rev. 2014;10(3):202-7. Review.</citation>
    <PMID>25088341</PMID>
  </reference>
  <reference>
    <citation>Sullivan S, Schanler RJ, Kim JH, Patel AL, Traw√∂ger R, Kiechl-Kohlendorfer U, Chan GM, Blanco CL, Abrams S, Cotten CM, Laroia N, Ehrenkranz RA, Dudell G, Cristofalo EA, Meier P, Lee ML, Rechtman DJ, Lucas A. An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products. J Pediatr. 2010 Apr;156(4):562-7.e1. doi: 10.1016/j.jpeds.2009.10.040. Epub 2009 Dec 29.</citation>
    <PMID>20036378</PMID>
  </reference>
  <reference>
    <citation>Cristofalo EA, Schanler RJ, Blanco CL, Sullivan S, Trawoeger R, Kiechl-Kohlendorfer U, Dudell G, Rechtman DJ, Lee ML, Lucas A, Abrams S. Randomized trial of exclusive human milk versus preterm formula diets in extremely premature infants. J Pediatr. 2013 Dec;163(6):1592-1595.e1. doi: 10.1016/j.jpeds.2013.07.011. Epub 2013 Aug 20.</citation>
    <PMID>23968744</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manitoba</investigator_affiliation>
    <investigator_full_name>Meghan Azad</investigator_full_name>
    <investigator_title>Prinicpal Investigator</investigator_title>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>At this time we plan to share IPD within our research team only. We will consider sharing with other researchers in the future.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

